Laboratory and clinical studies of mom(9, 3″-di-o-acetyl midecamycin) in pediatric field

Ryochi Fujii; Tatsuhiko Shinozaki; Hidenori Meguro; Shintaro Hashira; Yoriko Koike; Masatoshi Takimoto; Jun ichi Oki; Hajime Yoshioka; Aiko Takase; Ichimei Nagamatsu; Ryuzo Aoyama; Yoshiki Kakizaki; Akira Ohnishi; Makoto Fujita; Kishiro Nagata; Yukio Izumi; Naoko Sugaya; Mami Nanba; Yuri Okimoto; Akira Nakamura; Itaru Terashima; Suzuko Uehara; Susumu Nakazawa; Hajime Sato; Kenji Shinno; Yuichi Hirama; Akira Narita; Shin ichi Nakazawa; Shujiro Tikaoka; Tatue Tazoe; Kohji Yanagisawa; Hiroki Hoshina; Haruo Ichihashi; Ukio Iwasaki; Satoshi Iwata; Takefumi Kanemitu; Keiji Jozaki; Haruki Haatori; Ryo Wakabayashi; Yoshifumi Kojima; Tadatoshi Kuratsuji; Keisuke Sunakawa; Tadao Oikawa; Mituru Oshano; Yasuo Ichihashi; Makoto Hori; Yoshiie Kurosu; Yoshikiyo Toyoda; Morimasa Sugita; Mikio Minamitani; Kei Hachimori; Itsuo Minamikawa; Masatoshi Suzuki; Naoichi Iwai; Akira Sasaki; Yoichi Taneda; Fumiko Mizokuchi; Haruhi Nakamura; Tadafumi Nishimura; Toshio Takashima; Kenji Hiromatsu; Kazuo Tabuki; Michio Takagi; Yutaka Kobayashi; Tsunekazu Haruta; Shigekazu Kuroki; Kanetsu Ohkura

doi:10.11250/chemotherapy1953.31.53

Laboratory and clinical studies of mom(9, 3″-di-o-acetyl midecamycin) in pediatric field

Ryochi Fujii, Tatsuhiko Shinozaki, Hidenori Meguro, Shintaro Hashira, Yoriko Koike, Masatoshi Takimoto, Jun ichi Oki, Hajime Yoshioka, Aiko Takase, Ichimei Nagamatsu, Ryuzo Aoyama, Yoshiki Kakizaki, Akira Ohnishi, Makoto Fujita, Kishiro Nagata, Yukio Izumi, Naoko Sugaya, Mami Nanba, Yuri Okimoto, Akira NakamuraItaru Terashima, Suzuko Uehara, Susumu Nakazawa, Hajime Sato, Kenji Shinno, Yuichi Hirama, Akira Narita, Shin ichi Nakazawa, Shujiro Tikaoka, Tatue Tazoe, Kohji Yanagisawa, Hiroki Hoshina, Haruo Ichihashi, Ukio Iwasaki, Satoshi Iwata, Takefumi Kanemitu, Keiji Jozaki, Haruki Haatori, Ryo Wakabayashi, Yoshifumi Kojima, Tadatoshi Kuratsuji, Keisuke Sunakawa, Tadao Oikawa, Mituru Oshano, Yasuo Ichihashi, Makoto Hori, Yoshiie Kurosu, Yoshikiyo Toyoda, Morimasa Sugita, Mikio Minamitani, Kei Hachimori, Itsuo Minamikawa, Masatoshi Suzuki, Naoichi Iwai, Akira Sasaki, Yoichi Taneda, Fumiko Mizokuchi, Haruhi Nakamura, Tadafumi Nishimura, Toshio Takashima, Kenji Hiromatsu, Kazuo Tabuki, Michio Takagi, Yutaka Kobayashi, Tsunekazu Haruta, Shigekazu Kuroki, Kanetsu Ohkura

Research output: Contribution to journal › Article › peer-review

Abstract

The authors have carried out the laboratory and clinical studies of MOM and obtained the following results: 1. The sensitivities of S. aureus: 114 strains, S. pyogenes: 144 strains and S. pneumoniae'. 35 strains to MOM, MDM and EM were distributed widely. In particular, two peaks existed clearly in the distribution of sensitivities to EM. The sensitivity of the superior peak of these two was higher by one to three tubes than the peak of MOM in three species. However, the frequency of the resistant strains to EM was the highest among these three drugs. The sensitivities of B. pertussis: nine strains to these drugs were below 0. 39 μg/ml and those to EM were the highest. The sensitivities of H. influenzae: 12 strains to MOM and MDM were above 12. 5μg/ml. 2. The serum concentrations and urinary excretion rate of MOM dry syrup were measured in 22 pediatric patients by oral administration at the dose of 10 mg/kg and in 24 patients at the dose of 20 mg/kg. The peak of mean serum concentrations of MOM for the 10 mg/kg group and the 20 mg/kg group were 0.756 μg/ml and 1. 010 μg/ml respectively at one hour after administration. The mean urinary recovery rates of MOM for the former group and for the latter were 1.67% and 2.46% respectively for six hours after administration. 3. The clinical responses of MOM were excellent in 53 cases, good in 174, fair in 28 and poor in 45 out of 300 cases, i. e. 39 cases with pharyngitis, 57 with tonsillitis, 35 with bronchitis, 17 with pneumonia, 79 with mycoplasmal respiratory tract infection, 45 with scarlet fever, 26 with whooping cough, one with S. S. S. S. and one with otitis media. Overall efficacy rate was 75. 7%. The difference in the efficacy rate was not statistically significant when the clinical response was compared among groups of four different daily dose, i.e. below 20 mg/kg, 21∼30 mg/kg, 31∼40 mg/kg and above 41 mg/kg. Fifty-eitht out of 117 strains isolated were eradicated. The clinical side effects of MOM in 378 cases (including dropout cases) were observed in 14 cases (3. 70%), i. e. four cases of exanthema and 10 cases of gastrointestinal abnormality like diarrhea. No severe side effects like hepatitis were observed. As to the clinical laboratory findings of MOM, a slight elevation of GOT in three cases, GPT in two cases, GOT-GPT-total bilirubin in one case and the eosinophilia in four cases were observed, but these were mild.

Original language	English
Pages (from-to)	53-66
Number of pages	14
Journal	Chemotherapy
Volume	31
Issue number	1
DOIs	https://doi.org/10.11250/chemotherapy1953.31.53
Publication status	Published - 1983 Jan
Externally published	Yes

ASJC Scopus subject areas

Infectious Diseases
Pharmacology
Pharmacology (medical)
Drug Discovery
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.11250/chemotherapy1953.31.53

Cite this

Fujii, R., Shinozaki, T., Meguro, H., Hashira, S., Koike, Y., Takimoto, M., Oki, J. I., Yoshioka, H., Takase, A., Nagamatsu, I., Aoyama, R., Kakizaki, Y., Ohnishi, A., Fujita, M., Nagata, K., Izumi, Y., Sugaya, N., Nanba, M., Okimoto, Y., ... Ohkura, K. (1983). Laboratory and clinical studies of mom(9, 3″-di-o-acetyl midecamycin) in pediatric field. Chemotherapy, 31(1), 53-66. https://doi.org/10.11250/chemotherapy1953.31.53

Fujii, R, Shinozaki, T, Meguro, H, Hashira, S, Koike, Y, Takimoto, M, Oki, JI, Yoshioka, H, Takase, A, Nagamatsu, I, Aoyama, R, Kakizaki, Y, Ohnishi, A, Fujita, M, Nagata, K, Izumi, Y, Sugaya, N, Nanba, M, Okimoto, Y, Nakamura, A, Terashima, I, Uehara, S, Nakazawa, S, Sato, H, Shinno, K, Hirama, Y, Narita, A, Nakazawa, SI, Tikaoka, S, Tazoe, T, Yanagisawa, K, Hoshina, H, Ichihashi, H, Iwasaki, U, Iwata, S, Kanemitu, T, Jozaki, K, Haatori, H, Wakabayashi, R, Kojima, Y, Kuratsuji, T, Sunakawa, K, Oikawa, T, Oshano, M, Ichihashi, Y, Hori, M, Kurosu, Y, Toyoda, Y, Sugita, M, Minamitani, M, Hachimori, K, Minamikawa, I, Suzuki, M, Iwai, N, Sasaki, A, Taneda, Y, Mizokuchi, F, Nakamura, H, Nishimura, T, Takashima, T, Hiromatsu, K, Tabuki, K, Takagi, M, Kobayashi, Y, Haruta, T, Kuroki, S & Ohkura, K 1983, 'Laboratory and clinical studies of mom(9, 3″-di-o-acetyl midecamycin) in pediatric field', Chemotherapy, vol. 31, no. 1, pp. 53-66. https://doi.org/10.11250/chemotherapy1953.31.53

@article{d2814253b33f4a3c807b9d2354d46b6b,

title = "Laboratory and clinical studies of mom(9, 3″-di-o-acetyl midecamycin) in pediatric field",

abstract = "The authors have carried out the laboratory and clinical studies of MOM and obtained the following results: 1. The sensitivities of S. aureus: 114 strains, S. pyogenes: 144 strains and S. pneumoniae'. 35 strains to MOM, MDM and EM were distributed widely. In particular, two peaks existed clearly in the distribution of sensitivities to EM. The sensitivity of the superior peak of these two was higher by one to three tubes than the peak of MOM in three species. However, the frequency of the resistant strains to EM was the highest among these three drugs. The sensitivities of B. pertussis: nine strains to these drugs were below 0. 39 μg/ml and those to EM were the highest. The sensitivities of H. influenzae: 12 strains to MOM and MDM were above 12. 5μg/ml. 2. The serum concentrations and urinary excretion rate of MOM dry syrup were measured in 22 pediatric patients by oral administration at the dose of 10 mg/kg and in 24 patients at the dose of 20 mg/kg. The peak of mean serum concentrations of MOM for the 10 mg/kg group and the 20 mg/kg group were 0.756 μg/ml and 1. 010 μg/ml respectively at one hour after administration. The mean urinary recovery rates of MOM for the former group and for the latter were 1.67% and 2.46% respectively for six hours after administration. 3. The clinical responses of MOM were excellent in 53 cases, good in 174, fair in 28 and poor in 45 out of 300 cases, i. e. 39 cases with pharyngitis, 57 with tonsillitis, 35 with bronchitis, 17 with pneumonia, 79 with mycoplasmal respiratory tract infection, 45 with scarlet fever, 26 with whooping cough, one with S. S. S. S. and one with otitis media. Overall efficacy rate was 75. 7%. The difference in the efficacy rate was not statistically significant when the clinical response was compared among groups of four different daily dose, i.e. below 20 mg/kg, 21∼30 mg/kg, 31∼40 mg/kg and above 41 mg/kg. Fifty-eitht out of 117 strains isolated were eradicated. The clinical side effects of MOM in 378 cases (including dropout cases) were observed in 14 cases (3. 70%), i. e. four cases of exanthema and 10 cases of gastrointestinal abnormality like diarrhea. No severe side effects like hepatitis were observed. As to the clinical laboratory findings of MOM, a slight elevation of GOT in three cases, GPT in two cases, GOT-GPT-total bilirubin in one case and the eosinophilia in four cases were observed, but these were mild.",

author = "Ryochi Fujii and Tatsuhiko Shinozaki and Hidenori Meguro and Shintaro Hashira and Yoriko Koike and Masatoshi Takimoto and Oki, {Jun ichi} and Hajime Yoshioka and Aiko Takase and Ichimei Nagamatsu and Ryuzo Aoyama and Yoshiki Kakizaki and Akira Ohnishi and Makoto Fujita and Kishiro Nagata and Yukio Izumi and Naoko Sugaya and Mami Nanba and Yuri Okimoto and Akira Nakamura and Itaru Terashima and Suzuko Uehara and Susumu Nakazawa and Hajime Sato and Kenji Shinno and Yuichi Hirama and Akira Narita and Nakazawa, {Shin ichi} and Shujiro Tikaoka and Tatue Tazoe and Kohji Yanagisawa and Hiroki Hoshina and Haruo Ichihashi and Ukio Iwasaki and Satoshi Iwata and Takefumi Kanemitu and Keiji Jozaki and Haruki Haatori and Ryo Wakabayashi and Yoshifumi Kojima and Tadatoshi Kuratsuji and Keisuke Sunakawa and Tadao Oikawa and Mituru Oshano and Yasuo Ichihashi and Makoto Hori and Yoshiie Kurosu and Yoshikiyo Toyoda and Morimasa Sugita and Mikio Minamitani and Kei Hachimori and Itsuo Minamikawa and Masatoshi Suzuki and Naoichi Iwai and Akira Sasaki and Yoichi Taneda and Fumiko Mizokuchi and Haruhi Nakamura and Tadafumi Nishimura and Toshio Takashima and Kenji Hiromatsu and Kazuo Tabuki and Michio Takagi and Yutaka Kobayashi and Tsunekazu Haruta and Shigekazu Kuroki and Kanetsu Ohkura",

year = "1983",

month = jan,

doi = "10.11250/chemotherapy1953.31.53",

language = "English",

volume = "31",

pages = "53--66",

journal = "CHEMOTHERAPY",

issn = "0009-3165",

number = "1",

}

TY - JOUR

T1 - Laboratory and clinical studies of mom(9, 3″-di-o-acetyl midecamycin) in pediatric field

AU - Fujii, Ryochi

AU - Shinozaki, Tatsuhiko

AU - Meguro, Hidenori

AU - Hashira, Shintaro

AU - Koike, Yoriko

AU - Takimoto, Masatoshi

AU - Oki, Jun ichi

AU - Yoshioka, Hajime

AU - Takase, Aiko

AU - Nagamatsu, Ichimei

AU - Aoyama, Ryuzo

AU - Kakizaki, Yoshiki

AU - Ohnishi, Akira

AU - Fujita, Makoto

AU - Nagata, Kishiro

AU - Izumi, Yukio

AU - Sugaya, Naoko

AU - Nanba, Mami

AU - Okimoto, Yuri

AU - Nakamura, Akira

AU - Terashima, Itaru

AU - Uehara, Suzuko

AU - Nakazawa, Susumu

AU - Sato, Hajime

AU - Shinno, Kenji

AU - Hirama, Yuichi

AU - Narita, Akira

AU - Nakazawa, Shin ichi

AU - Tikaoka, Shujiro

AU - Tazoe, Tatue

AU - Yanagisawa, Kohji

AU - Hoshina, Hiroki

AU - Ichihashi, Haruo

AU - Iwasaki, Ukio

AU - Iwata, Satoshi

AU - Kanemitu, Takefumi

AU - Jozaki, Keiji

AU - Haatori, Haruki

AU - Wakabayashi, Ryo

AU - Kojima, Yoshifumi

AU - Kuratsuji, Tadatoshi

AU - Sunakawa, Keisuke

AU - Oikawa, Tadao

AU - Oshano, Mituru

AU - Ichihashi, Yasuo

AU - Hori, Makoto

AU - Kurosu, Yoshiie

AU - Toyoda, Yoshikiyo

AU - Sugita, Morimasa

AU - Minamitani, Mikio

AU - Hachimori, Kei

AU - Minamikawa, Itsuo

AU - Suzuki, Masatoshi

AU - Iwai, Naoichi

AU - Sasaki, Akira

AU - Taneda, Yoichi

AU - Mizokuchi, Fumiko

AU - Nakamura, Haruhi

AU - Nishimura, Tadafumi

AU - Takashima, Toshio

AU - Hiromatsu, Kenji

AU - Tabuki, Kazuo

AU - Takagi, Michio

AU - Kobayashi, Yutaka

AU - Haruta, Tsunekazu

AU - Kuroki, Shigekazu

AU - Ohkura, Kanetsu

PY - 1983/1

Y1 - 1983/1

N2 - The authors have carried out the laboratory and clinical studies of MOM and obtained the following results: 1. The sensitivities of S. aureus: 114 strains, S. pyogenes: 144 strains and S. pneumoniae'. 35 strains to MOM, MDM and EM were distributed widely. In particular, two peaks existed clearly in the distribution of sensitivities to EM. The sensitivity of the superior peak of these two was higher by one to three tubes than the peak of MOM in three species. However, the frequency of the resistant strains to EM was the highest among these three drugs. The sensitivities of B. pertussis: nine strains to these drugs were below 0. 39 μg/ml and those to EM were the highest. The sensitivities of H. influenzae: 12 strains to MOM and MDM were above 12. 5μg/ml. 2. The serum concentrations and urinary excretion rate of MOM dry syrup were measured in 22 pediatric patients by oral administration at the dose of 10 mg/kg and in 24 patients at the dose of 20 mg/kg. The peak of mean serum concentrations of MOM for the 10 mg/kg group and the 20 mg/kg group were 0.756 μg/ml and 1. 010 μg/ml respectively at one hour after administration. The mean urinary recovery rates of MOM for the former group and for the latter were 1.67% and 2.46% respectively for six hours after administration. 3. The clinical responses of MOM were excellent in 53 cases, good in 174, fair in 28 and poor in 45 out of 300 cases, i. e. 39 cases with pharyngitis, 57 with tonsillitis, 35 with bronchitis, 17 with pneumonia, 79 with mycoplasmal respiratory tract infection, 45 with scarlet fever, 26 with whooping cough, one with S. S. S. S. and one with otitis media. Overall efficacy rate was 75. 7%. The difference in the efficacy rate was not statistically significant when the clinical response was compared among groups of four different daily dose, i.e. below 20 mg/kg, 21∼30 mg/kg, 31∼40 mg/kg and above 41 mg/kg. Fifty-eitht out of 117 strains isolated were eradicated. The clinical side effects of MOM in 378 cases (including dropout cases) were observed in 14 cases (3. 70%), i. e. four cases of exanthema and 10 cases of gastrointestinal abnormality like diarrhea. No severe side effects like hepatitis were observed. As to the clinical laboratory findings of MOM, a slight elevation of GOT in three cases, GPT in two cases, GOT-GPT-total bilirubin in one case and the eosinophilia in four cases were observed, but these were mild.

AB - The authors have carried out the laboratory and clinical studies of MOM and obtained the following results: 1. The sensitivities of S. aureus: 114 strains, S. pyogenes: 144 strains and S. pneumoniae'. 35 strains to MOM, MDM and EM were distributed widely. In particular, two peaks existed clearly in the distribution of sensitivities to EM. The sensitivity of the superior peak of these two was higher by one to three tubes than the peak of MOM in three species. However, the frequency of the resistant strains to EM was the highest among these three drugs. The sensitivities of B. pertussis: nine strains to these drugs were below 0. 39 μg/ml and those to EM were the highest. The sensitivities of H. influenzae: 12 strains to MOM and MDM were above 12. 5μg/ml. 2. The serum concentrations and urinary excretion rate of MOM dry syrup were measured in 22 pediatric patients by oral administration at the dose of 10 mg/kg and in 24 patients at the dose of 20 mg/kg. The peak of mean serum concentrations of MOM for the 10 mg/kg group and the 20 mg/kg group were 0.756 μg/ml and 1. 010 μg/ml respectively at one hour after administration. The mean urinary recovery rates of MOM for the former group and for the latter were 1.67% and 2.46% respectively for six hours after administration. 3. The clinical responses of MOM were excellent in 53 cases, good in 174, fair in 28 and poor in 45 out of 300 cases, i. e. 39 cases with pharyngitis, 57 with tonsillitis, 35 with bronchitis, 17 with pneumonia, 79 with mycoplasmal respiratory tract infection, 45 with scarlet fever, 26 with whooping cough, one with S. S. S. S. and one with otitis media. Overall efficacy rate was 75. 7%. The difference in the efficacy rate was not statistically significant when the clinical response was compared among groups of four different daily dose, i.e. below 20 mg/kg, 21∼30 mg/kg, 31∼40 mg/kg and above 41 mg/kg. Fifty-eitht out of 117 strains isolated were eradicated. The clinical side effects of MOM in 378 cases (including dropout cases) were observed in 14 cases (3. 70%), i. e. four cases of exanthema and 10 cases of gastrointestinal abnormality like diarrhea. No severe side effects like hepatitis were observed. As to the clinical laboratory findings of MOM, a slight elevation of GOT in three cases, GPT in two cases, GOT-GPT-total bilirubin in one case and the eosinophilia in four cases were observed, but these were mild.

UR - http://www.scopus.com/inward/record.url?scp=0020662468&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020662468&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1953.31.53

DO - 10.11250/chemotherapy1953.31.53

M3 - Article

AN - SCOPUS:0020662468

SN - 0009-3165

VL - 31

SP - 53

EP - 66

JO - CHEMOTHERAPY

JF - CHEMOTHERAPY

IS - 1

ER -

Laboratory and clinical studies of mom(9, 3″-di-o-acetyl midecamycin) in pediatric field

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this